- Share Trading on London Stock Exchange Frozen
- Dubai Debt Delay Rattles Stock, Bond Markets
- Fannie Mae to Tighten Lending Standards: Report
- China Overcapacity Worsening, EU Chamber Warns
- Investing in Good Karma – and Making a Profit
- China Unveils Carbon Target Ahead of Copenhagen
- Wal-Mart Price Pressure Hurts China Workers: Report
- Black Friday to Avoid Red Ink; Greenback Gets the Blues
- Bankruptcies Jump, Hitting Highest Level in Four Years
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
MOST SHARED
- The Executive Job Search
- Where Do Pardoned Turkeys Go?
- Chinese Overcapacity is Worsening, EU Chamber Warns
- Salvation Army's Kettles Now Credit Card-Ready
- Activision Prepares to Double Dip on ‘Modern Warfare 2’
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- Dubai Debt Delay Rattles Stock, Bond Markets
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Topless Business Is Taking Off
Text Size 
Pfizer's acquisition of Wyeth will add to the pharmaceutical giant's diversity, which over time will help boost the company's stock, CEO Jeff Kindler told CNBC Tuesday.
"Ultimately, the way we increase the stock is by improving shareholder value in the long run," Kindler said. "Our prospects are very strong."
Pfizer [PFE
Loading...
()
] plans to cut about $4 billion in annual expenses after the acquisition is complete, and it will eliminate 15 percent of the companies' combined employees, he said.
Kindler added that management will discuss the future of the company's dividend in December, after cutting it in half to 64 cents earlier this year.
"We'll consider the importance of the dividend to our shareholders, which we understand very much," he said, "as well as all considerations about the best use of our capital for our shareholders."
On Tuesday, Pfizer reported third-quarter earnings that beat Wall Street's profit expectations as cost-cutting outweighed a decline in sales.
Also on CNBC.com:
Print
Email
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
- Eric Schmidt pledges to create a virtual copy of the Iraq National Museum at Google’s expense.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- More shoppers than ever plan to comparison-shop this season. Who will benefit?
- It may be the most unusual guide to business you'll read.
- How can you get out of debt and back on the road to recovery? Follow these ten steps.
Data is a real-time snapshot *Data is delayed at least 15 minutes